• Home
  • Articles
  • Dr. Eliaz Babaev
  • Michael Afremov
  • Senator Rudy Boschwitz
  • Blake Vanderhyde
  • More
    • Home
    • Articles
    • Dr. Eliaz Babaev
    • Michael Afremov
    • Senator Rudy Boschwitz
    • Blake Vanderhyde
  • Home
  • Articles
  • Dr. Eliaz Babaev
  • Michael Afremov
  • Senator Rudy Boschwitz
  • Blake Vanderhyde

Eliaz Babaev

Pioneer in Ultrasound Technology

Eliaz Babaev

Co-Founder, CEO, and President – Arobella Medical, LLC


Dr. Eliaz P. Babaev is a pioneering biomedical engineer with more than 50 years of expertise in non-imaging medical ultrasound, specializing in ultrasound wound management and live tissue repair. He is the Co-Founder, CEO, and President of Arobella Medical, LLC, and previously co-founded Celleration Inc., where he served as Chief Technology Officer and Chief Executive Officer. Earlier in his career, he led the Biomedical Engineering Laboratory at the State Technical University in Baku.


Dr. Babaev holds a Ph.D. in Biomechanical Engineering from Moscow-Bauman Technical University, and earned two Doctor of Science (D.Sc.) degrees—one in Biomedical Engineering (Medical Ultrasound) from the Latvian Academy of Science in 1993, and another in Biomedical Instrumentations and Biomechanics in 1991. He also earned both his B.S. and M.S. in Mechanical Engineering (Industrial Ultrasound for Oil Reservoirs) from Azerbaijan Technical University in 1969.


Throughout his career, Dr. Babaev has made groundbreaking contributions to wound care, tissue science, nursing, drug delivery systems, tissue engineering, cancer research (including apoptosis), and other advanced medical technologies. He is the inventor or co-inventor of more than 50 U.S. patents and over 100 international patents, with numerous additional applications pending. His research has been widely published in over 50 scientific articles and abstracts, advancing the fields of skin and wound healing, medical ultrasound, and biomedical engineering.


Copyright © 2026 Superbug Treatments - The Future of Medicine? - All Rights Reserved.     

FULL DISCLOSURE: This website is provided for informational and educational purposes only. It does not constitute an offer to sell securities, a solicitation of interest in any securities offering, medical advice, or investment advice. Certain statements in this article may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially, including but not limited to: failure of in vivo scientific validation, adverse FDA classification or pathway decisions, inability to secure development financing, unforeseen competitive developments, regulatory changes, and loss of key inventor knowledge. The antimicrobial applications discussed here are investigational and are not FDA-cleared for antimicrobial indications. As of the date of publication, no legal entity has been formed or identified for purposes of any securities offering related to this technology. Any future financing, if any, would be conducted only through formal offering materials and in compliance with applicable federal and state securities laws. Do not rely on this content for investment, legal, or medical decisions.

  • Articles

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept